Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Spyre Therapeutics, Inc.

NASDAQ: SYRE · Life Sciences · 6 alerts · CIK 1636282

Share price
$99.37Close, Nov 16
Market cap
$9.44B
Shares outstanding
94.97MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Spyre Therapeutics, Inc. filings on SEC EDGAR ↗

4:02 PM ET 8-K
Financial Results

Spyre Therapeutics Financial Results

Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.

Term
Q3 2026

“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”

Cameron Turtle, DPhil, Chief Executive Officer of Spyre
4:01 PM ET 10-Q
Financial Results

Spyre Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Widens

Spyre Therapeutics reported a significant increase in its financial position, with total current assets growing from $777.8 million at the end of 2025 to approximately $1.1 billion as of September 30, 2026, primarily driven by an increase in marketable securities. The company is advancing its clinical pipeline, including the SKYLINE and SKYLIGHT Phase 2 trials, while maintaining a large accelerated filer status.

Key figure
Net loss $96.1M
8:00 AM ET 8-K
Capital Raise

Spyre Therapeutics Capital Raise of $350M

Spyre Therapeutics entered into an underwriting agreement for a public offering of 4,117,648 shares of common stock at $85.00 per share, expected to raise gross proceeds of approximately $350.0 million. The company intends to use the proceeds to advance its clinical programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and a new program for hidradenitis suppurativa.

Value
$350M
Counterparty
Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated
9:30 PM ET Form 4
Insider Selling

Spyre Therapeutics Insider Heidy King-Jones Sells $2.63M of Stock

Heidy King-Jones sold 28,933 shares of Spyre Therapeutics, Inc. at $89.24 to $93.46 a share (average $91.03) in 5 transactions, worth $2.63M in total on Oct 1, 2026. Shares held after the trade: 2,845 (-47.8%).

Value
$2.63M
Shares
28,933
Average price
$91.03
Holding change
-47.8%
Trade date
Oct 1, 2026
9:30 PM ET Form 4
Insider Selling

Spyre Therapeutics CEO Cameron Turtle Sells $1.37M of Stock

Cameron Turtle, CEO, sold 14,900 shares of Spyre Therapeutics, Inc. at $89.14 to $93.37 a share (average $91.99) in 5 transactions, worth $1.37M in total on Oct 1, 2026. Shares held after the trade: 537,640 (-0.9%).

Value
$1.37M
Shares
14,900
Average price
$91.99
Role
CEO
Holding change
-0.9%
Trade date
Oct 1, 2026
9:29 PM ET Form 4
Insider Selling

Spyre Therapeutics CFO Scott L. Burrows Sells $2.26M of Stock

Scott L. Burrows, CFO, sold 25,000 shares of Spyre Therapeutics, Inc. at $89.07 to $93.57 a share (average $90.47) in 6 transactions, worth $2.26M in total between Sep 30, 2026 and Oct 1, 2026. Shares held after the trade: 79,762 (-0.3%).

Value
$2.26M
Shares
25,000
Average price
$90.47
Role
CFO
Holding change
-0.3%
Trade date
Sep 30, 2026 to Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.